Prostate Cancer is a primary cause of cancer deaths for men in the US in 2019, there were 174,650 men diagnosed with prostate cancer, according to the National Institute of Cancer. In the UK in 2017, Cancer Research reported about 48,600 new prostate cancer cases, representing 26% of all new cancer cases in males.
Various approaches exist for the treatment of prostate cancer: these include surgery, radiation therapy, proton therapy, cryotherapy, hormone therapy and chemotherapy. The external beam radiation therapy (EBRT) technique for this type of cancer delivers radiation by using photons, electrons and heavy particles such as carbon ions, neutrons and protons.
Multileaf collimators can shape the proton beam to conform to the target and limit the dose to surrounding healthy tissue. This approach would allow significant radiation dose to increase at the prostate cancer site. The next breakthrough in radiation therapy was intensity-modulated radiation therapy (IMRT), the most advanced method for delivering photon-based external beam radiation therapy (EBRT).
Hence, intensity-modulated radiation therapy (IMRT) employs computer algorithms to calculate the correct radiation dose for a specific target. This dose distribution is optimised by changing the beam’s intensity across the designated volume by splitting the beam into several smaller beamlets.
Consequently, each beamlet with variable intensity conforms to the irregular shape of the target and allows the surrounding healthy organs to be spared from unnecessary radiation.
The advancements in medical guidance systems, such as imaging equipment attached to the linear accelerator, have helped to deliver radiation more accurately to the prostate. These radiation therapy techniques have considerably decreased the ambiguity in target localisation and, consequently, the accuracy in the treatment of prostate cancer.
You are here:
home »
By | 4 minutes of readingAdvancing prostate cancer treatment, Lutetium-177 HTK03170 and Gallium-68 HTK03149 enable targeted PSMA therapy, improving diagnosis and therapeutic outcomes.
By | 4 minutes of readingLutetium-177 FAPI-04 revolutionises cancer treatment by precisely targeting cancer-associated fibroblasts, enabling dual imaging and radiotherapy functionalities for enhanced outcomes.
Innovative Radiotherapeutics: Lutetium-177 FAPI-04 as a Game-Changer in Cancer Treatment Read Post »
By | 7 minutes of readingTumour grading assesses cellular abnormality, predicting cancer growth rate, treatment needs, and informing patient prognosis effectively.
Decoding Cancer: How the Tumour Grading System Shapes Diagnosis and Treatment Read Post »
By | 6 minutes of readingProton radiation therapy revolutionises cancer treatment by precisely targeting tumours while sparing healthy tissues.
The Fascinating World of Proton Radiation Therapy Read Post »
By | 5 minutes of readingRadiopharmaceutical therapy in cancer offers targeted treatment, minimising side effects while enhancing patient outcomes.
Radiopharmaceutical Therapy in Cancer: A Beacon of Hope in Oncology Read Post »
By | 8 minutes of readingThis article explores cancer treatment advancements, tumour biology complexities, and the critical role of palliative care in oncology.
Advances in Oncology: Cancer Treatment, Tumour Biology, and Palliative Care Read Post »
By | 13 minutes of readingRadiotheranostics offers a precise, personalised approach to cancer treatment by combining diagnostic imaging with targeted therapy.
The Future of Radiotheranostics: A New Frontier in Precision Medicine Read Post »
By | 5 minutes of readingAdvancements in medical imaging technology are transforming cancer diagnosis, enabling more precise treatment planning and better patient outcomes.
Revolutionising Cancer Care: The Power of Medical Imaging Read Post »
By | 13 minutes of readingExploring the evolving role of radiopharmaceutical diagnostics in enhancing disease detection and personalising treatment in modern medicine.
Radiopharmaceutical Diagnostics and Imaging Technologies Read Post »
By | 16 minutes of readingAdvancing cancer care, proton therapy offers precise treatment with fewer side effects, revolutionising patient experiences.
Proton Therapy: The Future Of Precision Cancer Treatment Read Post »
By | 3 minutes of reading225Ac-FPI-2265, targeting PSMA, shows promise in treating advanced prostate cancer in the TATCIST clinical trial.
By | 5 minutes of readingPosluma (Flotufolastat F-18) offers precise PET imaging for detecting PSMA-positive prostate cancer lesions.
By | 5 minutes of readingRadium-223 dichloride, a targeted alpha therapy, effectively treats castration-resistant prostate cancer with bone metastases, improving patients’ overall survival.
By | 3 minutes of readingLutetium-177 Vipivotide Tetraxetan – Pluvicto: Radiopharmaceutical for targeted cancer therapy. Innovative, promising, precise, advanced, therapeutic.
By | 4 minutes of readingProstate cancer’s global impact persists; mCRPC, demanding advanced strategies, finds hope in 177Lu-PSMA targeted radioligand therapy.
By | 3 minutes of readingGallium-68 Gozetotide enhances PET imaging for oncology, targeting somatostatin receptors, and offering improved tumour detection and patient care.
Gallium-68 Gozetotide: A Radiopharmaceutical Agent for PET Imaging Read Post »
By | 2 minutes of readingCarbon-14 Choline, a radioactive isotope, improves medical imaging accuracy and expands molecular research, aiding cancer diagnosis and treatment.
Carbon-11 Choline: A Radiopharmaceutical with Expanding Applications Read Post »
By | 13 minutes of readingThese cancer destroying machines are capable of providing proton beam therapy via pencil beam scanning.
By | 22 minutes of readingEvaluation of metastatic castrate-resistant prostate cancer using fluorine-18 choline PET-CT imaging.
By | 10 minutes of readingEnchondroma is a benign bone tumor in the medullary cavity of bone.
By | 5 minutes of readingTopics on MRI, ablation, lacrimal scintigraphy and enchondroma.
Editorial review 2016 nuclear medicine, diagnostic imaging and therapy Read Post »
By | 12 minutes of readingA case report to analyse the role of abiraterone and volumetric-modulated arc therapy towards prostate cancer.
